Russian study of efficacy and safety of an angiotensin converting enzyme inhibitor quinapril in patients with hypertension
Karpov, I.A.; Deev, A.D.
Kardiologiia 43(6): 28-32
2003
ISSN/ISBN: 0022-9040 PMID: 12891308 Document Number: 556610
Efficacy and safety of an angiotensin converting enzyme inhibitor quinapril were assessed in a 12 week study on 258 patients with 1-2 degree hypertension and various concomitant pathology. The use of quinapril as monotherapy (10-40 mg/day) or in combination with hydrochlorothiazide (12.5 mg/day) was associated with blood pressure (BP) normalization (<140/90 mm Hg) or more then 10% BP lowering in 88% of patients. In the end of the study average blood pressure was 134/84 mm HG. Quinapril was well tolerated. These results allow to recommend the scheme of quinapril use utilized in the study for wide application for the treatment of outpatients with hypertension.